Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) SHZ
Currency In CNY
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CNY
Sector
Healthcare
Industry
Biotechnology
Employees
620
First IPO Date
June 16, 2020
| Name | Title | Pay | Year Born |
| Fu Wang | Vice President | 0 | 1969 |
| Hongbo Wu | President & Non-Independent Director | 0 | 1968 |
| Huaigong Chen | Vice President & Quality Manager | 0 | 1972 |
| Wennian Wu | Vice President, Chief Financial Officer, Secretary of the Board & Director | 0 | 1983 |
| Ping Liu | Accounting Supervisor | 0 | N/A |
Chengdu Kanghua Biological Products Co., Ltd. is a Chinese biopharmaceutical company that covers the entire lifecycle of its products, from research and development to production, sales, and technical service. Its current commercial offerings include group ACYW135 meningococcal polysaccharide vaccines and freeze-dried human diploid cell rabies vaccines. The company also has a robust development pipeline, featuring a preservative-free seasonal influenza vaccine that has successfully concluded Phase III clinical trials, as well as a human H5N1 influenza vaccine which has completed its pre-clinical studies. Established in 2004 and headquartered in Chengdu, China, the firm also distributes its products internationally.